Glypressine (Terlipressin Acetate)

Glypressine is indicated for the management of acute complications related to portal hypertension and renal perfusion. It is employed in clinical practice for the following purposes:

• Treatment of acute variceal bleeding in patients with liver cirrhosis.
• Management of hepatorenal syndrome to improve kidney function.
• Temporary reduction of portal pressure during endoscopic procedures.
• Supportive therapy in severe hypotension associated with septic shock when conventional vasopressors are insufficient.
• Adjunctive use in selected cases of refractory ascites under specialist guidance.

Side effects of Glypressine vary in frequency and severity. Common adverse reactions are typically mild and transient, while serious events are less frequent but require prompt medical attention.

Common

• Headache
• Nausea or vomiting
• Abdominal pain or cramps
• Flushing or warmth sensation
• Hypertension (elevated blood pressure)
• Peripheral edema

Serious

• Ischemic complications (e.g., myocardial, mesenteric, or peripheral ischemia)
• Severe hypertension leading to organ damage
• Cardiac arrhythmias
• Acute renal failure in susceptible individuals
• Allergic reactions such as anaphylaxis

Before initiating Glypressine, clinicians should evaluate patient-specific risk factors and monitor for potential complications. Important precautions include:

• Assess cardiovascular status, especially in patients with coronary artery disease or uncontrolled hypertension.
• Use cautiously in individuals with a history of ischemic bowel disease or peripheral vascular disease.
• Monitor renal function closely, particularly in patients with pre‑existing kidney impairment.
• Avoid use in pregnant women unless the potential benefit justifies the risk, as safety data are limited.
• Discontinue if signs of severe hypertension, ischemia, or allergic reaction develop.
• Ensure appropriate fluid and electrolyte balance during therapy.

Glypressine may interact with other medications that affect vascular tone, cardiac function, or renal perfusion. Consider the following interaction categories:

Avoid

• Concurrent use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that may exacerbate hypertension.
• Combination with drugs that prolong the QT interval, increasing arrhythmia risk.
• Simultaneous administration of non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients with compromised renal function.

Use with caution

• Beta‑blockers, which may mask tachycardia related to hypertension.
• Diuretics, as they can alter intravascular volume and affect blood pressure response.
• Anticoagulants, because changes in portal pressure may influence bleeding risk.
• Other vasoactive agents used in liver disease management, requiring close hemodynamic monitoring.